Silence Therapeutics PLC Grant of Share Options (6713N)
May 21 2020 - 10:28AM
UK Regulatory
TIDMSLN
RNS Number : 6713N
Silence Therapeutics PLC
21 May 2020
Grant of Share Options
21 May 2020
LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the
Company"), a leader in the discovery, development and delivery of
novel RNA therapeutics for the treatment of serious diseases,
advises that on 20 May 2020 new options have been issued to Iain
Ross, Executive Chairman, to acquire a total of 500,000 new
ordinary shares in the capital of the Company ("Ordinary Shares"),
under the Silence Therapeutics plc 2018 Long Term Incentive Plan.
Following this award Iain now has 1,000,000 options in the
Company.
350,000 options will be granted with a strike price of GBP4.40
and will vest quarterly over three years. 150,000 options will be
granted with a strike price of 5p, of which 100,000 will vest on
the third anniversary of Iain's appointment to the board in April
2019, subject to Silence achieving a listing on a US stock
exchange. The remaining 50,000 options at 5p will vest upon
achievement of a listing on a US stock exchange and subsequent
achievement of a share price of GBP4.40 over 30-days.
1. Details of the person discharging managerial responsibilities
(PDMR) / person closely associated
a) Name Iain Ross
--------------------------- -------------------------------------------------
2. Reason for the notification
------------------------------------------------------------------------------
a) Position / status Executive Chairman
--------------------------- -------------------------------------------------
b) Initial notification Initial notification
/ Amendment
--------------------------- -------------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------------
a) Name Silence Therapeutics plc
--------------------------- -------------------------------------------------
b) LEI 213800SSURRJBX85SQ91
--------------------------- -------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
------------------------------------------------------------------------------
a) Description of Options over Ordinary Shares in Silence
the financial instrument, Therapeutics Plc under the Silence Therapeutics
type of instrument plc 2018 Long Term Incentive Plan.
Identification
code ISIN for Silence Therapeutics plc Ordinary
Shares:
GB00B9GTXM62
--------------------------- -------------------------------------------------
b) Nature of the transaction Issue of options over Ordinary Shares
in Silence Therapeutics Plc
--------------------------- -------------------------------------------------
c) Prices(a) and volume(s) Options Awarded at Options Awarded at
GBP4.40 5p
350,000 150,000
-------------------
--------------------------- -------------------------------------------------
d) Aggregated information
- Aggregated volume See above
- Price
--------------------------- -------------------------------------------------
e) Date of the transaction 20 May 2020
--------------------------- -------------------------------------------------
f) Place of the transaction Off exchange
--------------------------- -------------------------------------------------
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20 3457
Iain Ross, Executive Chairman 6900
Dr Rob Quinn, Chief Financial Officer
Investec Bank plc (Nominated Adviser and Tel: +44 (0) 20
Broker) 7597 5970
Daniel Adams/Gary Clarence
European IR Tel: +44 (0) 20
Consilium Strategic Communications 3709 5700
Mary-Jane Elliott/Chris Welsh/Angela Gray
silencetherapeutics@consilium-comms.com
US IR Tel: +1 (443) 213-0505
Westwicke Partners
Peter Vozzo
peter.vozzo@westwicke.com
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural mechanism of RNA interference, or
RNAi, within its cells. Its proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the
production of disease-associated proteins. Silence's proprietary
RNA chemistries and delivery systems are designed to improve the
stability of molecules and enhance effective delivery to target
cells, providing a powerful modular technology well suited to
tackle life-threatening diseases. The Company has secured high
value research and collaboration agreements with AstraZeneca,
Mallinckrodt Pharmaceuticals and Takeda. For more information,
please visit: https://www.silence-therapeutics.com/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHKKDBBPBKDPPB
(END) Dow Jones Newswires
May 21, 2020 11:28 ET (15:28 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024